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ABSTRACT
Objective To examine the association between a
biomarker of exposure to secondhand smoke (salivary
cotinine concentration) and cognitive impairment.
Design Cross sectional analysis of a national population
based study.
Setting Stratified random sample of households
throughout England.
Participants 4809 non-smoking adults aged 50 years or
more from the 1998, 1999, and 2001 waves of the Health
Survey forEnglandwhoalsoparticipated in the2002waveof
theEnglishLongitudinalStudyofAgeingandprovidedsaliva
samples for cotinine assay and a detailed smoking history.
Main outcome measure Cognitive impairment as defined
by the lowest 10% of scores on a battery of
neuropsychological tests.
Results Participants who did not smoke, use nicotine
products, or have salivary cotinine concentrations of 14.1
ng/ml or more were divided into four equal size groups on
the basis of cotinine concentrations. Compared with the
lowest fourthof cotinineconcentration (0.0-0.1ng/ml) the
odds ratios (95% confidence intervals) for cognitive
impairment in the second (0.2-0.3 ng/ml), third (0.4-0.7
ng/ml), and highest fourths (0.8-13.5 ng/ml) were 1.08
(0.78 to 1.48), 1.13 (0.81 to 1.56), and1.44 (1.07 to 1.94;
P for trend 0.02), after adjustment for a wide range of
established risk factors for cognitive impairment. A similar
pattern of associations was observed for never smokers
and former smokers.
Conclusions Exposure to secondhand smoke may be
associated with increased odds of cognitive impairment.
Prospective nationally representative studies relating
biomarkers of exposure to cognitive decline and risk of
dementia are needed.
INTRODUCTION
Active smoking may be a risk factor for cognitive
impairment and dementia,1 although it is not clear
whether exposure to secondhand smoke is also a risk
factor. The health effects of high levels of exposure to
secondhand smoke may be close to those of active
smoking,2 including an increased risk of lung cancer,
diabetes, cardiovascular disease, hypertension, stroke,
and death.3-9 As the risks associated with secondhand
smoke have become clearer, an increasing number of
governments have decided to legislate against smoking
in public places.10 11 Given the association between
exposure to secondhand smoke and risk factors for
cognitive impairment such as cardiovascular disease46
and stroke,12 it is possible that such exposure may be a
preventable risk factor for cognitive impairment.
Previous findings also suggest that exposure to second-
hand smoke may be associated with poor cognitive
performance in children and adolescents.13-15
A preliminary analysis of 985 patients (728 women)
aged 66-92 years from the Cardiovascular Health
Study was carried out (T J Haight et al, 59th annual
meeting of the American Academy of Neurology,
Boston, 2007) and has been widely reported.16
Participants who had never smoked, had no history
of cardiovascular disease or dementia, and self
reported long term exposure to secondhand tobacco
smoke (livingwith a smoker for 30 years ormore) were
about 30% more likely to develop dementia over a six
year period than those who were not exposed (relative
hazard 1.3, 95% confidence interval 0.95 to 1.82). This
association did not, however, reach statistical signifi-
cance when adjusted for age, sex, and education
(P>0.05). In the same study, participants with sub-
clinical carotid artery disease who lived with a smoker
for 30 years or more were more likely to develop
dementia (relative hazard 2.38, 1.23 to 4.63), suggest-
ing a potential interaction between exposure to
secondhand smoke and subclinical cardiovascular
disease. Haight et al therefore hypothesised that
exposure to secondhand smoke may be detrimental
to cognitive health. Further research incorporating
population representative samples while controlling
for other factors that may be confounders is needed.
We examined the association between exposure to
secondhandsmokeandcognitive impairment ina large
population based sample of non-smokers.
METHODS
Participantswere fromthe1998,1999,and2001wavesof
theHealth Survey for England17 who also participated in
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the 2002 wave of the English Longitudinal Study of
Ageing.18 The Health Survey for England is a nationally
representativemultistage stratified random sample of the
community dwelling English population. The core
sample of the English Longitudinal Study of Ageing is
limited to adults aged 50 years or more in 2002 and is
drawn from the Health Survey for England sample by
postcode sector (geographical area), stratified by health
authority and proportion of households in non-manual
socioeconomic groups. Of 11234 people who took part
in both the Health Survey for England and the English
LongitudinalStudyofAgeing, 8893werenon-smokersat
both time points. Cotininemeasurements were obtained
for most of the eligible non-smoking participants in the
Health Survey for England waves 1998 (73%) and 2001
(70%), whereas only a randomly selected subsample of
participants received a nurse visit in the 1999 wave and
therefore provided a saliva sample (8%). We restricted
our analyses to the subsample of 5265 non-smoking
participants whose salivary cotinine levels were mea-
sured. We excluded 22 participants with a self reported
diagnosis of dementia, 205 participants who claimed to
be non-smokers but used nicotine products or had
salivary cotinine concentrations of 14.1 ng/ml or more
(considered to be active smokers),19 and 229 who had
missing values ononeormoreof the neuropsychological
measures used to assess cognitive impairment. The
remaining 4809 participants formed the sample for our
analyses.
Exposure to secondhand smoke
We used levels of salivary cotinine (ng/ml) measured
in the Health Survey for England as a biomarker for
recent exposure to secondhand smoke (cotinine is a
Table 1 | Characteristics of non-smoking study population*. Values are numbers (percentages) unless stated otherwise
Variables
All participants
(n=4809)
Cognitively normal
(n=4328)
Cognitively impaired
(n=481)
P for group
difference
Exposure to secondhand smoke
Median (interquartile range)† salivary cotinine
(ng/ml)
0.3 (0.1-0.7) 0.3 (0.1-0.7) 0.4 (0.1-1.0) <0.001
Additional variables
Mean (SD) age (years) 65.1 (10.3) 63.9 (9.7) 75.5 (9.9) <0.001
Women 2557 (53) 2288 (53) 269 (56) 0.2
White ethnic origin 4699 (98) 4244 (98) 455 (95) <0.001
Highest educational qualification:
None 1810 (38) 1451 (34) 359 (75)
<0.001Intermediate 1557 (32) 1475 (34) 82 (17)
Degree or higher 1442 (30) 1402 (32) 40 (8)
Manual occupational class 1822 (38) 1517 (35) 305 (63) <0.001
Health Survey for England wave:
1998 2468 (51) 2201 (51) 267 (56)
0.071999 124 (3) 109 (3) 15 (3)
2001 2217 (46) 2018 (47) 199 (41)
Median (interquartile range) net
non-housing wealth (£)
28 000 (4680-95 000) 31 688 (5600-101 512) 6400 (1500-30 504) <0.001
Smoking history:
Never smokers 2014 (42) 1839 (43) 175 (36)
0.03Former smokers (stopped <10 years ago) 655 (14) 582 (14) 73 (15)
Former smokers (stopped ≥10 years ago) 2140 (45) 1907 (44) 233 (48)
Obesity (body mass index >29.9)† 1137 (24) 1025 (24) 112 (23) 0.9
Physical inactivity 497 (10) 377 (9) 120 (25) <0.001
Alcohol consumption†:
0 g/day 481 (10) 372 (9) 109 (23)
<0.001>0-29.9 g/day 3848 (80) 3507 (81) 341 (70)
≥30 g/day 480 (10) 449 (10) 31 (6)
Depressive symptoms (CESD >3) 972 (20) 796 (18) 176 (37) <0.001
Diabetes 320 (7) 259 (6) 61 (13) <0.001
Cardiovascular disease 601 (13) 484 (11) 117 (24) <0.001
Stroke 172 (4) 131 (3) 41 (9) <0.001
Hypertension:
Untreated 475 (10) 436 (10) 39 (8)
0.001
Treated with antihypertensive drugs 1354 (28) 1183 (27) 171 (36)
CESD is eight item version of Center for Epidemiological Studies depression scale.34 35
*205 participants who claimed to be non-smokers but used nicotine products or had salivary cotinine concentration ≥14.1 ng/ml were considered
active smokers and were excluded.36 22 patients with a history of dementia were also excluded.
†Variables derived from Health Survey for England. All other variables derived from English Longitudinal Study of Ageing.
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metabolite of nicotine that has a half life of around
16-25 hours).20 Non-stimulated saliva samples were
collected according to theHealth Survey for England’s
protocol.17 Cotinine levels were analysed using a gas
chromatograph machine (hp5890; Hewlett Packard,
Palo Alto, CA, USA) with a rapid liquid chromato-
graphy technique by the Nicotine Laboratory at New
Cross Hospital in London.
Cognitive impairment
Cognitive impairment was assessed using neuropsy-
chological tests incorporated in the English Long-
itudinal Study of Ageing, which are described in detail
elsewhere.21 Briefly, attention and processing speed
were assessedusing the letter cancellation task from the
Medical Research Council National Study of Health
and Development.22 Time orientation was assessed
using questions from the mini-mental state
examination.23 Immediate and delayed verbal mem-
ory were assessed using a 10-word learning task from
the Health and Retirement Study.24 Prospective
memory was assessed by asking participants to
remember to write their initials in the top left corner
of apieceof paperona clipboardwhen itwashanded to
them later in the session (closely based on a task
incorporated in the Medical Research Council Cogni-
tive Function and Ageing Study),25 and by asking
participants to remind the interviewer to record the
time when he or she announced that the cognitive
section was finished. Numeracy was assessed using
questions relating to simple calculations based on
everyday situations, and these items have also been
incorporated in the Health and Retirement Study.24
The semantic verbal fluency task was taken from the
Cambridge cognitive examination (CAMCOG),26
which examines how many unique animals people
are able to name in one minute.
As the scoring of each individual test varied, we
obtained a global cognitive function score by summing
the standardised scores on each neuropsychological
test. Such composite scores are regularly used because
they integrate information from a variety of sources
and thus provide a more stable representation of
cognitive function than a single test.27 28 We defined
cognitive impairment as the lowest 10% of the
distribution of cognitive performance. Such a popula-
tion based cut-off point is a sensitive and specific
marker of cognitive impairment29 and has been used in
previous studies.30 31
Statistical analysis
We used multivariable logistic regression models to
determine the cross sectional relation between expo-
sure to secondhand smoke and cognitive impairment.
We adjusted for key personal and known risk factors
for cognitive impairment32 33: age, sex, ethnicity,
education (highest educational qualification), manual
occupational class, fourths of net non-housing wealth
(measured in pounds sterling), smoking history (never
smokers, former smokers who stopped smoking less
than 10 years ago, former smokers who stopped
smoking 10 years or more ago), obesity (body mass
index >29.9), alcohol consumption (g/day), physical
inactivity (participating in sport or physical activity less
than once a month), and depressive symptoms (more
than three symptoms on the eight item version of the
Center for Epidemiological Studies depression
scale).34 35 Variables for adjustment were derived
from the English Longitudinal Study of Ageing, with
the exception of obesity and alcohol consumption,
which were derived from the Health Survey for
England.
In a secondary analysis we examined whether any
observed association was mediated by a history of
medical conditions thought to be associated with
smoke inhalation (diabetes, cardiovascular disease,
stroke, untreated and treated hypertension).3-9 12 We
analysed former smokers and never smokers sepa-
rately and investigated whether the same pattern of
associations was observed if cognition was operationa-
lised as a continuous variable (global cognitive func-
tion) in multivariable linear regression models. In line
with the preliminary analysis of Haight et al (59th
annual meeting of the American Academy of Neurol-
ogy) we also investigated the potential interaction
between exposure to secondhand smoke and cardio-
Table 2 | Logistic regression models illustrating odds of cognitive impairment (95% confidence intervals) in 4809 non-smokers
by salivary cotinine levels
Variable
Basic adjusted
model*
Fully adjusted
model†
Fully adjusted model
plus medical history‡
Salivary cotinine fourths (ng/ml):
Lowest (0.0-0.1) Reference Reference Reference
Second (0.2-0.3) 1.13 (0.83 to 1.54) 1.08 (0.78 to 1.48) 1.08 (0.79 to 1.48)
Third (0.4-0.7) 1.26 (0.92 to 1.72) 1.13 (0.81 to 1.56) 1.12 (0.81 to 1.56)
Highest (0.8-13.5) 1.68 (1.27 to 2.22) 1.44 (1.07 to 1.94) 1.44 (1.07 to 1.93)
P for trend <0.001 0.02 0.02
Population weights used to adjust for sampling design.
*Adjusted for age, sex, education, and testing interval.
†Adjusted for age, sex, education, testing interval, ethnicity, manual occupation, net wealth, smoking history, obesity, alcohol consumption, physical
inactivity, and depressive symptoms.
‡Adjusted for age, sex, education, testing interval, ethnicity, manual occupation, net wealth, smoking history, obesity, alcohol consumption, physical
inactivity, depressive symptoms, history of medical conditions (diabetes, cardiovascular disease, stroke, untreated hypertension, and hypertension
treated with antihypertensive drugs).
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vascular disease. To take account of potential bias from
non-response we used population weights from the
English Longitudinal Study of Ageing to make the
respondent sample more representative of the
population.18 Non-response to the Health Survey for
England and theEnglish Longitudinal Study ofAgeing
both have the potential tomake the respondent sample
unrepresentative of the population. We therefore
inverted the predicted probability of response for the
responding households to provide the initial non-
response weight. A further round of weighting was
needed to adjust the initial household non-response
weight to ensure that the weighted sample of respon-
ders closely matched the older English population. In
addition, clusters and strata were used to allow for the
original complex sample design of the Health Survey
for England. We used Stata SE version 9.2 for all
analyses (StataCorp, College Station, TX).
RESULTS
Table 1 shows the characteristics of those included in
the analysis. Median salivary cotinine levels were low.
Thepatternsofpotential confoundersobservedwere in
keepingwith thegeneralpopulation.Theproportionof
former smokers who stopped smoking more than
10 years ago was similar to those who never smoked.
Most participants consumed alcohol, and about one in
10 were physically inactive. A large proportion of the
study population was obese and had significant
depressive symptoms or hypertension.
Non-smokers with valid cotinine measurements
(n=4809) were similar to the total eligible non-smoking
sample from the English Longitudinal Study of Ageing
(n=8061) for age (65.1 v 65.7 years), sex (53.2% v 55.3%
women), ethnic origin (97.7% v 97.6% white), educa-
tion (37.6% v 40.0% with no qualifications), and
occupational class (37.9% v 38.6% manual).
Logistic regression was used to determine the
relation between exposure to secondhand smoke and
cognitive impairment innon-smokers (table 2).Adjust-
ments were made for age, sex, education, and testing
interval (basic adjusted models), and then additional
covariables (fully adjusted models) were added (see
table 2). Those with high levels of salivary cotinine
(0.8-13.5 ng/ml) were more likely to be cognitively
impaired (odds ratio 1.44, 95% confidence interval
1.07 to 1.94) than those exposed to little or no
secondhand smoke (0.0-0.1 ng/ml). Some evidence
was found of a linear trend that might indicate a dose-
response relation (P=0.02). Additional adjustment for
medical conditions such as cardiovascular disease had
little effect.
Never smokers exposed to the highest levels of
secondhand smoke (salivary cotinine concentrations
0.8-13.5 ng/ml) were more likely to be cognitively
impaired (odds ratio 1.70, 1.03 to 2.80) than those
exposed to littleornosecondhandsmoke (0.0-0.1ng/ml;
table 3).Former smokers exposed to thehighest levels of
secondhand smoke also had increased odds of cognitive
impairment (1.32, 0.92 to 1.91), although this association
was weaker than that observed for never smokers.
The same pattern of associationswas observedwhen
cognitive function was analysed as a continuous
variable across fourths of cotinine concentration for
both basic models (P for trend <0.001) and fully
adjusted models (P for trend 0.025). The introduction
of an interaction term to the fully adjusted logistic
regression model indicated that there was no statisti-
cally significant interaction between history of cardio-
vascular disease and exposure to secondhand smoke
(P>0.2).
DISCUSSION
High levels of salivary cotinine in non-smoking adults
may be associated with increased odds of cognitive
impairment. A similar pattern of results was observed
for never and former smokers, and there was no
interaction with a history of cardiovascular disease.
Strengths and limitations
This analysis is to our knowledge the first to examine
the relation between exposure to secondhand smoke
and cognitive impairment in a large heterogeneous
population based sample. We controlled for a wide
range of covariables that are potential confounders in
cognitive research and incorporated an objective
biomarker for exposure to secondhandsmoke (salivary
cotinine concentration). Comparisons with census
Table 3 | Logistic regression models illustrating odds of cognitive impairment (95% confidence intervals) in former and never
smokers by salivary cotinine levels
Variable
Never smokers (n=2014) Former smokers (n=2795)
Basic adjusted model* Fully adjusted model† Basic adjusted model* Fully adjusted model†
Salivary cotinine fourths
(ng/ml):
Lowest (0.0-0.1) Reference Reference Reference Reference
Second (0.2-0.3) 1.44 (0.90 to 2.31) 1.42 (0.88 to 2.31) 0.95 (0.63 to 1.45) 0.88 (0.57 to 1.34)
Third (0.4-0.7) 1.26 (0.77 to 2.08) 1.16 (0.68 to 1.97) 1.26 (0.85 to 1.86) 1.11 (0.74 to 1.67)
Highest (0.8-13.5) 1.75 (1.10 to 2.78) 1.70 (1.03 to 2.80) 1.62 (1.14 to 2.30) 1.32 (0.92 to 1.91)
P for trend 0.03 0.08 0.005 0.1
Population weights used to adjust for sampling design.
*Adjusted for age, sex, education, and testing interval.
†Adjusted for age, sex, education, testing interval, ethnicity, manual occupation, net wealth, smoking history, obesity, alcohol consumption, physical
inactivity, and depressive symptoms.
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results show that the sample from the English Long-
itudinal Study of Ageing has a similar sociodemo-
graphic profile to the community living English
population.18
Several methodological issues should be considered
when interpretingour findings.The inclusionof former
smokers is potentially problematic as historical expo-
sure may be dominated by the former smoker’s own
previous smoking behaviours, and misclassification of
current smoking statusmaybeparticularly likely in this
group, leading to a residual confounding effect. We
carried out analyses separately for former and never
smokers, however, and the association between
cotinine levels and cognitive impairment seemed
stronger in never smokers. We also adjusted for
smoking history as a potential confounder, including
numberof years since stopping smoking. Furthermore,
we excluded 205 participants who claimed to be non-
smokers but used nicotine products or had salivary
cotinine concentrations of 14.1 ng/ml or more as we
considered them to be active smokers.19 Although
cotinine is a valid, sensitive and specific biomarker for
recent exposure to secondhand smoke,37 it does not
necessarily reflect exposure over the long period
duringwhich cognitive impairment typically develops.
However, cotinine levels have proved to be a useful
marker of general levels of exposure to secondhand
smoke.37 38 We analysed a series of cross sectional data
acquired over a mean of 2.6 years and did not find a
causal relation. Although we controlled for a wide
range of potential confounders the possibility of
residual confounding remains. Non-smokers with
valid cotinine measurements had a similar socio-
demographic profile to the total non-smoking sample
of the English Longitudinal Study of Ageing, and these
variables were controlled for in the analyses, making
systematic bias unlikely.
Comparison with previous studies
Haight et al (59th annual meeting of the American
Academy of Neurology) reported a non-significant
trend between self reported exposure to secondhand
smoke and risk of incident dementia in never smokers
over a six year period. Their sample comprised almost
exclusively women, whereas our sample was more
heterogeneous. It is possible that their findings were
not significant because of the reliance on self reported
exposure. Self report measures of secondhand expo-
sure have several important limitations—for example,
living with a smoker captures less than half of the
variation in cotinine concentration in non-smokers39
and does not take into account exposure in workplaces
and public places. The association we observed
between objectively measured cotinine levels and
cognitive impairment is consistent with studies sug-
gesting that active smoking may be a risk factor for
cognitive impairment and dementia,1 and that expo-
sure to secondhand smoke is associated with poor
cognitive performance in children and adolescents.13-15
Possible mechanisms
Several mechanisms have been proposed to explain
why exposure to secondhand smoke may increase the
odds of cognitive impairment. Exposure to second-
hand smoke is associated with an increased risk of
cardiovascular disease,4 6 and cardiovascular disease
may in turn be associated with an increased risk of
cognitive impairment and dementia.40 41 While addi-
tional adjustment for medical history made little
difference to the fully adjusted model, and no inter-
action between cotinine levels and a history of cardio-
vascular disease was observed, it is possible that
exposure to secondhand smoke may interact with
subclinical cardiovascular disease, as observed by
Haight et al (59th annual meeting of the American
Academy of Neurology). Another study discovered
that short term exposure to secondhand smoke
adversely affects endothelial function in ways that
immediately compromise the cardiovascular system.42
Dysfunctional endothelial cells contribute to vasocon-
striction, atherogenesis, and thrombosis and may
therefore compromise the blood supply to the brain.
Exposure to secondhand smoke is also a risk factor for
incident stroke,12 and differences in subclinical
cerebrovascular disease may help to explain the
noticeable individual differences in cognitive function
observed during late adulthood.43 Reverse causality is
also possible—for example, participantswith cognitive
impairment may metabolise nicotine differently from
those without cognitive impairment.
Conclusions
Our results suggest that in a large diverse sample of
non-smoking adults, high levels of cotinine may be
associated with increased odds of cognitive impair-
ment. Given the ongoing international policy debate
on exposure to secondhand smoke, this is a topic of
major public health significance. Prospective nation-
ally representative studies of the association between
biomarkers of exposure to secondhand smoke and
cognitive decline and dementia are therefore war-
ranted to assess the relation between secondhand
smoke and cognitive health with greater precision. In
the meantime, our results provide new evidence to
WHAT IS ALREADY KNOWN ON THIS TOPIC
Active smokingmaybea risk factor for cognitive impairment,
although it is not clear whether exposure to secondhand
smoke is a risk factor
No previous study has examined the association between
biomarkersofexposure tosecondhandsmokeandcognitive
impairment
WHAT THIS STUDY ADDS
In a large diverse sample of non-smoking adults, high levels
of cotininewere associatedwith increasedoddsof cognitive
impairment
A similar pattern of results was observed for never and
former smokers, and there was no interaction with a history
of cardiovascular disease
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suggest that exposure to secondhand smoke may be
associated with increased odds of cognitive impair-
ment.
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